Trial reportBlood2015
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Bridging the Gap: Cost-Effective Strategies for Detecting Ph-Like B-Lineage ALL in Resource-Limited Settings.Molecular diagnosis & therapy · 2025Review
- PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.Frontiers in pharmacology · 2024Review
- Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Cell death & disease · 2023Article
- The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.Annals of hematology · 2023Article
- Article
- Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.Cancer gene therapy · 2022Article
- Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.Cancer science · 2022Article
- The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders.Journal of neurochemistry · 2021Review
- Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.Cancer communications (London, England) · 2021Article
- Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system.Nature communications · 2021Article
- CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.Leukemia & lymphoma · 2021Article
- First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2020Review
- Chaperome Networks - Redundancy and Implications for Cancer Treatment.Advances in experimental medicine and biology · 2020Review
- Genetic variants and clinical significance of pediatric acute lymphoblastic leukemia.Annals of translational medicine · 2019Article
- Chaperome heterogeneity and its implications for cancer study and treatment.The Journal of biological chemistry · 2019Review
- Adapting to stress - chaperome networks in cancer.Nature reviews. Cancer · 2018Review
- Article
- Proteomic interrogation of HSP90 and insights for medical research.Expert review of proteomics · 2017Review
- [Research progress in Ph-like childhood acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 2 countries.
Nicole KucineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY;
Sachie MarubayashiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Neha BhagwatHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; Gerstner Sloan Kettering Graduate School in Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY;
Efthymia PapalexiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Priya KoppikarHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Marta Sanchez MartinInstitute for Cancer Genetics, Columbia University, New York, NY;
Lauren DongHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Marty S TallmanLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY;
Elisabeth PaiettaDivision of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY;
Kai WangFoundation Medicine, Cambridge, MA;
Jie HeFoundation Medicine, Cambridge, MA;
Doron LipsonFoundation Medicine, Cambridge, MA;
Phil StephensFoundation Medicine, Cambridge, MA;
Vince MillerFoundation Medicine, Cambridge, MA;
Jacob M RoweDepartment of Hematology and Bone Marrow Transplantation, The Rambam Medical Center, Haifa, Israel;
Julie Teruya-FeldsteinDepartment of Pathology, Icahn School of Medicine, Mount Sinai, New York, NY;
Charles G MullighanDepartment of Pathology and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN; and.
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, NY;
Andrei KrivtsovCancer Biology and Genetics Program, Center for Epigenetics Research, and.
Scott ArmstrongCancer Biology and Genetics Program, Center for Epigenetics Research, and.
Laura LeungHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Stefan O OchianaMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Gabriela ChiosisMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; Center for Epigenetics Research, and.
Maria KleppeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Memorial Sloan Kettering Cancer Center · USFoundation Medicine (United States)Cancer Genetics (United States) · USAlbert Einstein College of Medicine · USColumbia University · USIcahn School of Medicine at Mount Sinai · USRambam Health Care Campus · ILSt. Jude Children's Research Hospital · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI CHIOSIS, GABRIELA · 2015 to 2019
$6.7MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MBiomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9MTargeting the heat shock response for the therapy of DLBCLR01CA155226 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIOSIS, GABRIELA, MELNICK, ARI M. · 2011 to 2015
$2.5MNCATS NIH HHS UL1 TR000457NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA155226NCI NIH HHS R01 CA172546NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA196172NCRR NIH HHS UL1 RR024996
Abstract
The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL). However, the limited ability of JAK inhibition to induce molecular or clinicopathological responses in MPNs suggests a need for development of better therapies for JAK kinase-dependent malignancies. Here, we demonstrate that heat shock protein 90 (HSP90) inhibition using a purine-scaffold HSP90 inhibitor in early clinical development is an effective therapeutic approach in JAK-dependent ALL and can overcome persistence to JAK-inhibitor therapy in ALL cells.
Indexed as
HSP90 Heat-Shock ProteinsJanus Kinase 1Janus Kinase 2Neoplasm ProteinsPrecursor Cell Lymphoblastic Leukemia-LymphomaAnimalsBenzodioxolesFemaleHumansMaleMiceMutationPurinesXenograft Model Antitumor Assays9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-BenzodioxolesHSP90 Heat-Shock ProteinsJAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2Neoplasm ProteinsPurines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.